Related Experiment Video

Updated: Aug 8, 2025

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

1.0K

Different interventions for the treatment of patent ductus arteriosus in children: a protocol for a network

Xin Zhang1,2, Xiao-Dong Hou2,3, Wen-Xin Wang1,2

  • 1The First School of Clinical Medicine of Gansu University of Chinese Medicine, Lanzhou, China.

Systematic Reviews
|March 2, 2023
PubMed

Insights

This study compares the effectiveness and safety of various treatments for patent ductus arteriosus (PDA), a common congenital heart defect. A Bayesian network meta-analysis will determine the best intervention sequence for PDA children.

Area of Science:

  • Cardiology
  • Pediatric Cardiology
  • Medical Interventions

Background:

  • Patent ductus arteriosus (PDA) is a prevalent congenital heart disease requiring timely intervention.
  • Current treatment options for PDA include pharmacological therapy, surgical closure, and interventional closure.
  • The comparative effectiveness and safety of these interventions remain a subject of debate.

Purpose of the Study:

  • To conduct a Bayesian network meta-analysis to assess the efficacy and safety of different interventions for PDA.
  • To estimate the optimal sequence of therapies for PDA management in children.
  • To provide a comprehensive comparison of various PDA treatment modalities.

Main Methods:

  • A systematic search of multiple databases (PubMed, Embase, Cochrane Library, Web of Science, etc.) will be performed.
  • Data extraction and reporting will adhere to PRISMA-P guidelines for Bayesian network meta-analysis.
  • Outcomes include PDA closure rates, success rates, mortality, procedure times, and complication rates. Study quality will be assessed using ROB and GRADE.

Main Results:

  • This section is not applicable as the study is a protocol and results are yet to be determined.
  • The study protocol outlines the planned analysis of primary and overall PDA closure, technical and surgical success rates.
  • Planned analysis includes assessment of mortality, operation time, ICU stay, radiation exposure, and complication rates.

Conclusions:

  • This Bayesian network meta-analysis aims to clarify the optimal treatment strategy for PDA.
  • The findings will inform clinical decision-making regarding the management of PDA in pediatric patients.
  • This research will contribute to evidence-based guidelines for PDA treatment.
Abstract

More Related Videos

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence10:52

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence

Published on: December 23, 2022

3.4K
A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

6.4K

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
31
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
16
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
238
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
479
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
213